In last trading session, Dare Bioscience Inc (NASDAQ:DARE) saw 0.33 million shares changing hands with its beta currently measuring 1.29. Company’s recent per share price level of $0.31 trading at $0.0 or -0.26% at ring of the bell on the day assigns it a market valuation of $31.30M. That closing price of DARE’s stock is at a discount of -241.94% from its 52-week high price of $1.06 and is indicating a premium of 12.9% from its 52-week low price of $0.27. Taking a look at company’s average trading volume volume of 669.93K if we extend that period to 3-months.
Dare Bioscience Inc (NASDAQ:DARE) trade information
Upright in the red during last session for losing -0.26%, in the last five days DARE remained trading in the green while hitting it’s week-highest on Tuesday, 04/30/24 when the stock touched $0.31 price level, adding 20.59% to its value on the day. Dare Bioscience Inc’s shares saw a change of 0.71% in year-to-date performance and have moved 1.73% in past 5-day. Dare Bioscience Inc (NASDAQ:DARE) showed a performance of -38.86% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dare Bioscience Inc (DARE) estimates and forecasts
Statistics highlight that Dare Bioscience Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -24.10% of value to its shares in past 6 months, showing an annual growth rate of 37.14% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 456.30% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 260k for the same. And 2 analysts are in estimates of company making revenue of 13.03M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 26.02% during past 5 years.
DARE Dividends
Dare Bioscience Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
